Royalty Pharma (RPRX) Gains from Investment Securities (2020 - 2026)
Royalty Pharma (RPRX) reported Gains from Investment Securities of $3.7 million for Q1 2026, down 72.22% on a YoY basis from $13.4 million in Q1 2025, and up 313.56% sequentially from $900000.0 in Q3 2025.
Royalty Pharma (RPRX) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Royalty Pharma (RPRX) has 7 years of Gains from Investment Securities data on file, last reported at $3.7 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 72.22% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 62.42% YoY), and the FY2025 full-year result was $13.4 million, changed 0.0% from the prior year.
- Gains from Investment Securities advanced to $3.7 million in Q1 2026, from $900000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $20.7 million in Q1 2022 to a low of $313000.0 in Q3 2023.
- A 5-year average of $7.0 million and a median of $5.8 million in 2022 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities sank 94.62% in 2023 and soared 80.0% in 2025, its largest moves.
- Tracing RPRX's Gains from Investment Securities over 5 years: stood at $5.8 million in 2022, then plunged by 94.63% to $313000.0 in 2023, then soared by 59.74% to $500000.0 in 2024, then soared by 80.0% to $900000.0 in 2025, then soared by 313.56% to $3.7 million in 2026.
- Business Quant data shows RPRX's Gains from Investment Securities at $3.7 million in Q1 2026, $900000.0 in Q3 2025, and $600000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Royalty Pharma | 25.71 Bn | 25.10 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.72 Mn |
| Mar 31, 2026 | 3.72 Mn |
| Sep 30, 2025 | 900,000.00 |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Mar 31, 2025 | 13.40 Mn |
| Mar 31, 2025 | 13.40 Mn |
| Sep 30, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 13.40 Mn |
| Mar 31, 2024 | 13.40 Mn |
| Sep 30, 2023 | 313,000.00 |
| Sep 30, 2023 | 313,000.00 |
| Jun 30, 2023 | 2.24 Mn |
| Jun 30, 2023 | 2.24 Mn |
| Mar 31, 2023 | 16.27 Mn |
| Mar 31, 2023 | 16.27 Mn |
| Dec 31, 2022 | 5.83 Mn |
| Dec 31, 2022 | 5.83 Mn |